Compare AGD & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AGD | GOSS |
|---|---|---|
| Founded | 2006 | 2015 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 288.1M | 796.2M |
| IPO Year | N/A | 2019 |
| Metric | AGD | GOSS |
|---|---|---|
| Price | $11.59 | $2.88 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $8.60 |
| AVG Volume (30 Days) | 61.2K | ★ 4.4M |
| Earning Date | 01-01-0001 | 11-05-2025 |
| Dividend Yield | ★ 8.13% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $44,051,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $6.41 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.20 | $0.76 |
| 52 Week High | $9.78 | $3.87 |
| Indicator | AGD | GOSS |
|---|---|---|
| Relative Strength Index (RSI) | 46.70 | 39.59 |
| Support Level | $11.71 | $3.04 |
| Resistance Level | $12.30 | $3.87 |
| Average True Range (ATR) | 0.21 | 0.29 |
| MACD | 0.01 | -0.10 |
| Stochastic Oscillator | 26.80 | 1.49 |
Aberdeen Global Dynamic Dividend Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current dividend income, more than 50% of which qualifies for the reduced federal income tax rate, as created by the Jobs and Growth Tax Relief Reconciliation Act of 2003. The fund also focuses on the long-term growth of capital as a secondary investment objective. The fund's portfolio holdings are in information technology, financials, health care, and consumer discretionary sectors among others.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.